Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.
Type:
Grant
Filed:
March 14, 2017
Date of Patent:
May 3, 2022
Assignee:
Universitetet | Oslo
Inventors:
Jan Terje Andersen, Stian Foss, Inger Sandlie
Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Type:
Grant
Filed:
August 17, 2017
Date of Patent:
April 19, 2022
Assignee:
University of Washington
Inventors:
Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.
Type:
Grant
Filed:
September 30, 2016
Date of Patent:
March 29, 2022
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere
Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
March 8, 2022
Assignee:
AMGEN INC.
Inventors:
Colin V. Gegg, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.
Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
Type:
Grant
Filed:
December 14, 2015
Date of Patent:
February 22, 2022
Assignees:
The Regents of the University of California, Seattle Children's Hospital
Inventors:
Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
Type:
Grant
Filed:
March 12, 2019
Date of Patent:
January 11, 2022
Assignee:
UCB Biopharma SPRL
Inventors:
Paul Alan Atherfold, Thomas Allen Ceska, Helene Margaret Finney, Lara Kevorkian, Kaushik Sarkar, Bryan John Smith, Kerry Louise Tyson
Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
Type:
Grant
Filed:
September 10, 2018
Date of Patent:
December 28, 2021
Assignee:
Cancer Research Technology LTD.
Inventors:
Michael Super, Jonathan Davis, Pascal Andre Stein
Abstract: Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins.
Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
Type:
Grant
Filed:
September 20, 2017
Date of Patent:
December 14, 2021
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
Type:
Grant
Filed:
April 25, 2019
Date of Patent:
December 7, 2021
Assignee:
Genentech, Inc.
Inventors:
Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle Dicara, Diego Ellerman, Christoph Spiess, Paul J. Carter
Abstract: An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more FcyR1-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.
Type:
Grant
Filed:
February 11, 2015
Date of Patent:
November 30, 2021
Assignees:
Albany Medical College, University of Washington through its Center for Commercialization
Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
Type:
Grant
Filed:
September 22, 2020
Date of Patent:
November 2, 2021
Assignees:
The Regents of the University of California, Seattle Children's Hospital
Inventors:
Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
Abstract: The current invention involves a series of fully recombinant multimerized forms of immunoglobulin Fc which thereby present polyvalent immunoglobulin Fc to immune cell receptors. The fusion proteins exist as both homodimeric and highly ordered multimeric fractions, termed stradomers. In comparison to the homodimeric fraction, purified multimeric stradomers have higher affinity and avidity for Fc?Rs with slower dissociation and are useful in the treatment and prevention of disease. The current invention demonstrates that directly linking IgG1 Fc regions to multimerization domains leads to enhanced multimerization and biological activity.
Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
August 24, 2021
Assignee:
MacroGenics, Inc.
Inventors:
Leslie S. Johnson, Ling Huang, Robyn Gerena
Abstract: Provided herein are heteromultimer constructs with reduced or silenced effector function. In an embodiment is provided a heteromultimer construct comprising an IgG Fc construct having a first and a second Fc polypeptide, each Fc polypeptide comprising a modified lower hinge region wherein: the modified lower hinge region of said first Fc polypeptide comprises at least one amino acid modification, the modified lower hinge region of said second Fc polypeptide comprises at least one amino acid modification which is different from at least one amino acid modification of said first Fc polypeptide, and the IgG Fc construct displays reduced binding to all Fc? receptors and to C1q protein as compared to a corresponding parent IgG Fc construct. Also provided are methods of producing such heteromultimer constructs, and methods of reducing ADCC for an antibody construct by reducing effector function.
Abstract: In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.
Type:
Grant
Filed:
August 11, 2018
Date of Patent:
July 13, 2021
Assignee:
Research Development Foundation
Inventors:
George Georgiou, Chang-Han Lee, Tae Hyun Kang
Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
June 15, 2021
Assignee:
University of Washington
Inventors:
Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
Abstract: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.
Type:
Grant
Filed:
October 17, 2011
Date of Patent:
June 8, 2021
Assignee:
NOVAGEN HOLDING CORPORATION
Inventors:
Haitao Wang, Yong Du, Rui Zhang, Jing Xu, Longbin Liu